Department of Internal Medicine, University of Genoa, Genoa, Italy.
J Investig Allergol Clin Immunol. 2010;20(4):274-9.
Quality of life (QOL) is an important issue in allergic rhinitis and has been evaluated in a number of studies that have shown how it is impaired in untreated patients and improved by effective treatment. However, there are no data concerning QOL after sublingual immunotherapy (SLIT) in polysensitized patients.
To evaluate the effect, in real-life clinical practice, of SLIT on QOL in a population of polysensitized patients with allergic rhinitis.
We prospectively evaluated 167 consecutively enrolled polysensitized patients with allergic rhinitis. QOL was measured in all cases with the Rhinoconjunctivitis Quality of Life Questionnaire at baseline and after 1 year of SLIT (performed in approximately 70% of cases using single allergen extracts provided by the same manufacturer).
The most frequent causes of sensitization were grass pollen, Parietaria, and house dust mites. The mean number of sensitizations per patient was 3.65. SLIT was performed with 1 extract in 123 patients (73.6%), with 2 extracts in 31 patients (18.6%), and with more than 2 extracts in 13 patients (7.8%). The mean values of all the QOL items improved significantly (P < .01 in all cases), with the following reductions noted: activities, 3.96 to 2.89; sleep, 2.07 to 1.56; general problems, 2.16 to 1.5; practical problems, 3.69 to 2.58; nasal symptoms, 3.57 to 2.50; eye symptoms, 2.92 to 1.83; and emotional aspects, 2.2 to 1.44.
This study provides evidence that QOL can be improved in polysensitized patients treated with SLIT, and that the use of just 1 or 2 allergen extracts seems to be sufficient and effective in terms of improving QOL.
生活质量(QOL)是变应性鼻炎的一个重要问题,已有多项研究评估了未经治疗的患者生活质量受损情况,以及有效治疗后的改善情况。然而,对于舌下免疫疗法(SLIT)治疗后多敏患者的生活质量,尚无相关数据。
评估 SLIT 在多敏的变应性鼻炎患者中的实际临床疗效对生活质量的影响。
我们前瞻性评估了 167 例连续入组的多敏变应性鼻炎患者。所有患者均采用 Rhinoconjunctivitis Quality of Life Questionnaire 进行生活质量评估,在基线时和 SLIT 治疗 1 年后进行(约 70%的患者使用同一制造商提供的单一过敏原提取物进行治疗)。
最常见的致敏原是草花粉、豚草和屋尘螨。每位患者的平均致敏原数量为 3.65。123 例患者(73.6%)使用 1 种提取物进行 SLIT,31 例患者(18.6%)使用 2 种提取物,13 例患者(7.8%)使用超过 2 种提取物。所有生活质量项目的平均值均显著改善(所有病例 P<.01),其中:活动受限,从 3.96 降至 2.89;睡眠障碍,从 2.07 降至 1.56;总体问题,从 2.16 降至 1.50;实际问题,从 3.69 降至 2.58;鼻部症状,从 3.57 降至 2.50;眼部症状,从 2.92 降至 1.83;情绪方面,从 2.2 降至 1.44。
本研究表明,SLIT 可改善多敏患者的生活质量,且使用 1 或 2 种过敏原提取物在提高生活质量方面似乎是足够和有效的。